Literature DB >> 21518756

Dynamic interdomain interactions contribute to the inhibition of matrix metalloproteinases by tissue inhibitors of metalloproteinases.

Albert G Remacle1, Sergey A Shiryaev, Ilian A Radichev, Dmitri V Rozanov, Boguslaw Stec, Alex Y Strongin.   

Abstract

Because of their important function, matrix metalloproteinases (MMPs) are promising drug targets in multiple diseases, including malignancies. The structure of MMPs includes a catalytic domain, a hinge, and a hemopexin domain (PEX), which are followed by a transmembrane and cytoplasmic tail domains or by a glycosylphosphatidylinositol linker in membrane-type MMPs (MT-MMPs). TIMPs-1, -2, -3, and -4 are potent natural regulators of the MMP activity. These are the inhibitory N-terminal and the non-inhibitory C-terminal structural domains in TIMPs. Based on our structural modeling, we hypothesized that steric clashes exist between the non-inhibitory C-terminal domain of TIMPs and the PEX of MMPs. Conversely, a certain mobility of the PEX relative to the catalytic domain is required to avoid these obstacles. Because of its exceedingly poor association constant and, in contrast with TIMP-2, TIMP-1 is inefficient against MT1-MMP. We specifically selected an MT1-MMP·TIMP-1 pair to test our hypothesis, because any improvement of the inhibitory potency would be readily recorded. We characterized the domain-swapped MT1-MMP chimeras in which the PEX of MMP-2 (that forms a complex with TIMP-2) and of MMP-9 (that forms a complex with TIMP-1) replaced the original PEX in the MT1-MMP structure. In contrast with the wild-type MT1-MMP, the diverse proteolytic activities of the swapped-PEX chimeras were then inhibited by both TIMP-1 and TIMP-2. Overall, our studies suggest that the structural parameters of both domains of TIMPs have to be taken into account for their re-engineering to harness the therapeutic in vivo potential of the novel TIMP-based MMP antagonists with constrained selectivity.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21518756      PMCID: PMC3121501          DOI: 10.1074/jbc.M110.200139

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  64 in total

Review 1.  Structure and function of matrix metalloproteinases and TIMPs.

Authors:  Hideaki Nagase; Robert Visse; Gillian Murphy
Journal:  Cardiovasc Res       Date:  2006-01-05       Impact factor: 10.787

2.  The isolated N-terminal domains of TIMP-1 and TIMP-3 are insufficient for ADAM10 inhibition.

Authors:  Magdalini Rapti; Susan J Atkinson; Meng-Huee Lee; Andrew Trim; Marcia Moss; Gillian Murphy
Journal:  Biochem J       Date:  2008-04-15       Impact factor: 3.857

3.  Flexibility and variability of TIMP binding: X-ray structure of the complex between collagenase-3/MMP-13 and TIMP-2.

Authors:  K Maskos; R Lang; H Tschesche; W Bode
Journal:  J Mol Biol       Date:  2006-12-01       Impact factor: 5.469

4.  Crystal structure of the catalytic domain of matrix metalloproteinase-1 in complex with the inhibitory domain of tissue inhibitor of metalloproteinase-1.

Authors:  Shalini Iyer; Shuo Wei; Keith Brew; K Ravi Acharya
Journal:  J Biol Chem       Date:  2006-10-18       Impact factor: 5.157

5.  The transmembrane domain is essential for the microtubular trafficking of membrane type-1 matrix metalloproteinase (MT1-MMP).

Authors:  Albert G Remacle; Dmitri V Rozanov; Peter C Baciu; Alexei V Chekanov; Vladislav S Golubkov; Alex Y Strongin
Journal:  J Cell Sci       Date:  2005-10-11       Impact factor: 5.285

6.  Tissue inhibitor of metalloproteinases-2 binding to membrane-type 1 matrix metalloproteinase induces MAPK activation and cell growth by a non-proteolytic mechanism.

Authors:  Silvia D'Alessio; Giovanni Ferrari; Karma Cinnante; William Scheerer; Aubrey C Galloway; Daniel F Roses; Dmitri V Rozanov; Albert G Remacle; Eok-Soo Oh; Sergey A Shiryaev; Alex Y Strongin; Giuseppe Pintucci; Paolo Mignatti
Journal:  J Biol Chem       Date:  2007-11-08       Impact factor: 5.157

Review 7.  MT4-(MMP17) and MT6-MMP (MMP25), A unique set of membrane-anchored matrix metalloproteinases: properties and expression in cancer.

Authors:  Anjum Sohail; Qing Sun; Huiren Zhao; M Margarida Bernardo; Jin-Ah Cho; Rafael Fridman
Journal:  Cancer Metastasis Rev       Date:  2008-06       Impact factor: 9.264

8.  Constraining specificity in the N-domain of tissue inhibitor of metalloproteinases-1; gelatinase-selective inhibitors.

Authors:  Asmaa B Hamze; Shuo Wei; Harinath Bahudhanapati; Smitha Kota; K Ravi Acharya; Keith Brew
Journal:  Protein Sci       Date:  2007-07-27       Impact factor: 6.725

9.  Multi-step pericellular proteolysis controls the transition from individual to collective cancer cell invasion.

Authors:  Katarina Wolf; Yi I Wu; Yueying Liu; Jörg Geiger; Eric Tam; Christopher Overall; M Sharon Stack; Peter Friedl
Journal:  Nat Cell Biol       Date:  2007-07-08       Impact factor: 28.824

10.  MMP-2 regulates human platelet activation by interacting with integrin alphaIIbbeta3.

Authors:  W-S Choi; O-H Jeon; H-H Kim; D-S Kim
Journal:  J Thromb Haemost       Date:  2007-12-12       Impact factor: 5.824

View more
  7 in total

1.  siRNA knockdown of tissue inhibitor of metalloproteinase-1 in keloid fibroblasts leads to degradation of collagen type I.

Authors:  Masayo Aoki; Koichi Miyake; Rei Ogawa; Teruyuki Dohi; Satoshi Akaishi; Hiko Hyakusoku; Takashi Shimada
Journal:  J Invest Dermatol       Date:  2013-09-16       Impact factor: 8.551

2.  Rubiarbonone C inhibits platelet-derived growth factor-induced proliferation and migration of vascular smooth muscle cells through the focal adhesion kinase, MAPK and STAT3 Tyr705 signalling pathways.

Authors:  Hyun-Soo Park; Khong Trong Quan; Joo-Hui Han; Sang-Hyuk Jung; Do-Hyung Lee; Eunji Jo; Tae-Wan Lim; Kyung-Sun Heo; MinKyun Na; Chang-Seon Myung
Journal:  Br J Pharmacol       Date:  2017-09-22       Impact factor: 8.739

Review 3.  Matrix metalloproteinase 14 modulates signal transduction and angiogenesis in the cornea.

Authors:  Jin-Hong Chang; Yu-Hui Huang; Christy M Cunningham; Kyu-Yeon Han; Michael Chang; Motoharu Seiki; Zhongjun Zhou; Dimitri T Azar
Journal:  Surv Ophthalmol       Date:  2015-12-02       Impact factor: 6.048

4.  Non-destructive and selective imaging of the functionally active, pro-invasive membrane type-1 matrix metalloproteinase (MT1-MMP) enzyme in cancer cells.

Authors:  Albert G Remacle; Sergey A Shiryaev; Vladislav S Golubkov; John N Freskos; Michael A Brown; Amolkumar S Karwa; Arati D Naik; Carol P Howard; Carolyn J Sympson; Alex Y Strongin
Journal:  J Biol Chem       Date:  2013-06-03       Impact factor: 5.157

Review 5.  Cell-cell and cell-matrix dynamics in intraperitoneal cancer metastasis.

Authors:  Katharine L Sodek; K Joan Murphy; Theodore J Brown; Maurice J Ringuette
Journal:  Cancer Metastasis Rev       Date:  2012-06       Impact factor: 9.264

6.  TIMP-1 induces an EMT-like phenotypic conversion in MDCK cells independent of its MMP-inhibitory domain.

Authors:  Young Suk Jung; Xu-Wen Liu; Rosemarie Chirco; Richard B Warner; Rafael Fridman; Hyeong-Reh Choi Kim
Journal:  PLoS One       Date:  2012-06-11       Impact factor: 3.240

7.  Selective function-blocking monoclonal human antibody highlights the important role of membrane type-1 matrix metalloproteinase (MT1-MMP) in metastasis.

Authors:  Albert G Remacle; Piotr Cieplak; Dong Hyun Nam; Sergey A Shiryaev; Xin Ge; Alex Y Strongin
Journal:  Oncotarget       Date:  2017-01-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.